NCOA2 and sarcoma: MCS diagnosis can be confirmed by the presence of NKX3.1 on immunostaining6 and detection of the NCOA2 gene rearrangements and fusions (such as HEY1‐NCOA2) and can now be incorporated into the group of translocation‐related sarcomas,7 which may yield biological insight into future treatments.8, 9